However, it will in the end be slide 10 (the most RIGHT part of it) that will make the news. That is the REAL value of Bavituximab which keeps it from keeping patients on a drug leach for the rest of their live and let our immune system LEARN to prevent a next occurrence. With ONLY blocking suppression and without the activation/stimulation part the auto-immune system would never learn the problem and build some specialized anti-body for next discovery. The Rahul guy on the Q/CC got that and CEO King's answer was all saying, almost relieved that finally someone on Wall Street understood that activating the immune system is a PROCESS involving MORE then attacking cell's only.
Furthermore from slide 11 (plus your friend scientist's explanation) I think one can appreciate what FINANCIAL treat Bavituximab is to many pipelines.
Everything that from close or far in its cycle is based on avoiding bindings with PS can simply be thrown away. Since PPHM with bavituximab binds PS itself there is no more need to directly or indirectly block PS receptors.
Market Data 
Markets 
AI
